Delivery Order 75N95021D00024-75N98026F00001

Award Date 9/18/21

Potential Completion Date 9/12/27

Potential Value $93K

Funding Federal Agency

National Institute on Drug Abuse

Contracting Federal Agency

Office of Logisitics and Acquisition Operations

Awardee

Murty Pharmaceuticals, Inc. DNJBTJ3XBQM6

Ultimate Awardee

Not listed

NAICS Category

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

PSC Category

AN12 - Health R&D Services; Health Care Services; Applied Research

Set-Aside Type

No Set-Aside Used

Federal Contract Vehicle

Not listed

Extent Competed

Full and Open Competition

Major Defense Program

Not listed

Pricing Type

Firm Fixed Price

Place of Performance

Lexington, KY 40509, USA

Solicitation Procedures

Negotiated Proposal / Quote

Number Of Offers Received

Not listed

Legislative Mandate

Service Contract Act

National Interest Action

Not listed

Research Type

Not listed

Primary Consortia Member

Not listed

The National Institute on Drug Abuse issued a delivery order to Murty Pharmaceuticals, Inc. on September 18, 2021, with a ceiling value of $92,724 for drug product stability studies under a firm fixed-price structure.

The order covers the development and manufacture of pharmaceutical products for the treatment of substance use disorder, with performance of work in Lexington, Kentucky. The period of performance runs from September 13, 2026, through September 12, 2027. Murty Pharmaceuticals is a minority-owned small disadvantaged business specializing in pharmaceutical research, development, and manufacturing for addiction treatment.

Generated 8/26/26, 9:57 AM